Results 21 to 30 of about 50,558 (217)

The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration [PDF]

, 2011
The relationship between lopinavir plasma concentration and the magnitude of lipid elevation after initiation of lopinavir/ritonavir-containing antiretroviral therapy is unclear.
Burger, David M., Sven A Danner, Michiel A van Agtmael, Veldkamp, Agnes I., van Vonderen, Marit G. A., Reiss, Peter, Agnes I Veldkamp, Danner, Sven A., Bierman, Wouter F. W., David M Burger, Peter Reiss, Wouter FW Bierman, van Agtmael, Michiel A., Marit GA van Vonderen   +13 more
core   +2 more sources

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

Clinical Case Reports, 2020
Key Clinical Message The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that
Hayato Koba, Taro Yoneda, Tomoya Kaneda, Tsukasa Ueda, Hideharu Kimura, Kazuo Kasahara   +5 more
doaj   +1 more source

Ritonavir Form III: A New Polymorph After 24 Years [PDF]

, 2022
Polymorphism occurs widely in pharmaceutical solids, and must be thoroughly studied during product development. Twenty-four years after ritonavir (RTV) Form II materialized, we report a new polymorph, Form III, discovered via melt crystallization.
Xin, Yao, GEOFF, ZHANG, Rodger, Henry
core   +1 more source

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Frontiers in Pharmacology, 2021
Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing.Methods:
Mario Karolyi, Sara Omid, Erich Pawelka, Bernd Jilma, Thomas Stimpfl, Christian Schoergenhofer, Hermann Laferl, Tamara Seitz, Marianna Traugott, Christoph Wenisch, Alexander Zoufaly   +10 more
doaj   +1 more source

Nirmatrelvir-ritonavir et simvastatine

, 2023
International audienceNirmatrelvir-ritonavir et simvastatine L'association nirmatrelvir-ritonavir est indiquée dans le traitement de la Covid-19 chez les patients adultes qui présentent un risque accru d'évolution vers une forme sévère.
Legeay, Samuel, Faure, Sébastien
core   +1 more source

The Plasma, Whole Blood and Intracellular Concentrations of Antiretroviral Agents in South African Children Receiving Combination Antiretroviral Therapy with and without Concomitant Antitubercular Treatment [PDF]

, 2009
Background: Tuberculosis (TB) is the most common opportunistic infection in children with human immunodeficiency virus (HIV) infection in developing countries, and co-treatment for HIV infection and TB is frequently indicated.
Ren, Yuan
core   +1 more source

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C [PDF]

Терапевтический архив, 2019
Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods.
E A Klimova, E Z Burnevich, V P Chulanov, D A Gusev, O O Znoyko, S N Batskikh, S N Kizlo, N A Mamonova, E P Tarkhova, E N Krasavina, M Yu Samsonov, N D Yushchuk   +11 more
doaj   +1 more source

Risk of acute liver injury following the nirmatrelvir/ritonavir use [PDF]

, 2023
Background: Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC-HR trial.Aim: To quantify the risk and severity of acute liver injury (ALI ...
Lau, Kristy Tsz Kwan, Kristy Tsz Kwan Lau, Eric Ho Yin Lau, Benjamin J. Cowling, Leung, Gabriel M, Mak, Lung Yi, Lung Yi Mak, Au, Ivan Chi Ho, Yuen, Man Fung, Wing Yiu Cheng, Ivan Chi Ho Au, Ching Hei So, Wong, Carlos King Ho, So, Ching Hei, Cowling, Benjamin J, Carlos King Ho Wong, Gabriel M. Leung, Lau, Eric Ho Yin, Man Fung Yuen, Cheng, Wing Yiu   +19 more
core   +2 more sources

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019 [PDF]

The Korean Journal of Internal Medicine, 2021
Background/Aims The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19).
Ji-Won Kim, Eun Jin Kim, Hyun Hee Kwon, Chi Young Jung, Kyung Chan Kim, Jung-Yoon Choe, Hyo-Lim Hong   +6 more
doaj   +1 more source

Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China

BMJ Open Respiratory Research
Background While simnotrelvir-ritonavir and nirmatrelvir-ritonavir, the oral antiviral agents targeting the 3C-like proteases, are widely used in China, robust data on their appropriate use remain limited in hospitalised patients.
Hui Zhang, Hui Yang, Yi Zhang, Jia Li, Han Wu, Xintong Zhang, Zhuoling An, Yuezhen Zhu, Chunguo Jiang, Wanying Chen   +9 more
doaj   +1 more source